IGC - India Globalization Capital climbs 11% on update for clinical trial on Alzheimer's patients

India Globalization Capital (IGC) announces the progress of its tetrahydrocannabinol (or THC)-based phase 1 clinical trial, which was approved to proceed by FDA on July 30, 2020.On February 11, the company completed administering the first of three levels of dosing of IGC-AD1.“While it has taken a long time to get to this trial, with many hurdles crossed along the way, including restrictions due to the Covid-19 pandemic, we are excited to have begun administering IGC-AD1, which uses a plant-derived cannabinoid, in an active trial. While others have focused on CBD (cannabidiol), the non-psychoactive component of cannabis, our trial is focused on THC, the psychoactive component. There is no known cure for Alzheimer’s disease, but we believe that THC, in combination with other drugs, may help with the management of Alzheimer’s patients, improve patient lifestyle, and bring a certain degree of relief for their caregivers,” said Ram Mukunda, CEO.Shares +11% pre market

For further details see:

India Globalization Capital climbs 11% on update for clinical trial on Alzheimer’s patients